Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

1.

A multicenter, phase II, randomized, non-comparative clinical trial of radiation and temozolomide with or without vandetanib in newly-diagnosed glioblastoma patients.

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow B, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon SH, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor T, Ligon KL, Wen PY.

Clin Cancer Res. 2015 Apr 24. pii: clincanres.3220.2014. [Epub ahead of print]

PMID:
25910950
2.

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB.

Lung Cancer. 2015 Apr;88(1):108-11. doi: 10.1016/j.lungcan.2015.01.020. Epub 2015 Feb 4.

PMID:
25682925
3.
4.

A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma.

Wang F, Remke M, Bhat K, Wong ET, Zhou S, Ramaswamy V, Dubuc A, Fonkem E, Salem S, Zhang H, Hsieh TC, O'Rourke ST, Wu L, Li DW, Hawkins C, Kohane IS, Wu JM, Wu M, Taylor MD, Wu E.

Oncotarget. 2015 Feb 20;6(5):2709-24.

5.

The Enhanced Workflow and Efficiency of the Wireless Local Area Network (WLAN)-Based Direct Digital Radiography (DDR) Portable Radiography.

Ngan TL, Wong ET, Ng KL, Jeor PK, Lo GG.

J Digit Imaging. 2015 Jan 6. [Epub ahead of print]

PMID:
25561071
6.

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY.

Neurology. 2015 Jan 20;84(3):280-6. doi: 10.1212/WNL.0000000000001153. Epub 2014 Dec 19.

PMID:
25527270
7.

A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time.

Li YC, Rodewald LW, Hoppmann C, Wong ET, Lebreton S, Safar P, Patek M, Wang L, Wertman KF, Wahl GM.

Cell Rep. 2014 Dec 11;9(5):1946-58. doi: 10.1016/j.celrep.2014.10.058. Epub 2014 Nov 20.

8.

A feature analysis of lower solubility proteins in three eukaryotic systems.

Albu RF, Chan GT, Zhu M, Wong ET, Taghizadeh F, Hu X, Mehran AE, Johnson JD, Gsponer J, Mayor T.

J Proteomics. 2015 Apr 6;118:21-38. doi: 10.1016/j.jprot.2014.10.011. Epub 2014 Oct 25.

PMID:
25451012
9.

Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.

Kanner AA, Wong ET, Villano JL, Ram Z; EF-11 Investigators.

Semin Oncol. 2014 Oct;41 Suppl 6:S25-34. doi: 10.1053/j.seminoncol.2014.09.008. Epub 2014 Sep 16.

10.

Response patterns of recurrent glioblastomas treated with tumor-treating fields.

Vymazal J, Wong ET.

Semin Oncol. 2014 Oct;41 Suppl 6:S14-24. doi: 10.1053/j.seminoncol.2014.09.009. Epub 2014 Sep 16.

11.

Psychosocial perception of adults with onychomycosis: a blinded, controlled comparison of 1,017 adult Hong Kong residents with or without onychomycosis.

Chan HH, Wong ET, Yeung CK.

Biopsychosoc Med. 2014 Jul 15;8:15. doi: 10.1186/1751-0759-8-15. eCollection 2014.

12.

The natural history of intravascular lymphomatosis.

Fonkem E, Lok E, Robison D, Gautam S, Wong ET.

Cancer Med. 2014 Aug;3(4):1010-24. doi: 10.1002/cam4.269. Epub 2014 Jun 14.

13.

NUCKS is a positive transcriptional regulator of insulin signaling.

Qiu B, Shi X, Wong ET, Lim J, Bezzi M, Low D, Zhou Q, Akıncılar SC, Lakshmanan M, Swa HL, Tham JM, Gunaratne J, Cheng KK, Hong W, Lam KS, Ikawa M, Guccione E, Xu A, Han W, Tergaonkar V.

Cell Rep. 2014 Jun 26;7(6):1876-86. doi: 10.1016/j.celrep.2014.05.030. Epub 2014 Jun 12.

14.

Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3 Tesla.

Scheidegger R, Wong ET, Alsop DC.

Neuroimage. 2014 Oct 1;99:256-68. doi: 10.1016/j.neuroimage.2014.05.036. Epub 2014 May 20.

PMID:
24857712
15.

Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab.

Elzinga G, Wong ET.

Case Rep Neurol. 2014 Apr 5;6(1):109-15. doi: 10.1159/000362264. eCollection 2014 Jan.

16.

Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.

Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, DiMeglio L, Davies AM, Wong ET.

Semin Oncol. 2014 Jun;41 Suppl 4:S1-14. doi: 10.1053/j.seminoncol.2014.03.011. Epub 2014 Mar 19.

17.

Qualitative assessment of pain management in patients undergoing computed tomography-guided transthoracic lung biopsy.

Wong ET, Dunham C, Patsios D.

Pain Res Manag. 2014 May-Jun;19(3):149-52. Epub 2014 Apr 22.

18.

Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma.

Wong ET, Lok E, Swanson KD, Gautam S, Engelhard HH, Lieberman F, Taillibert S, Ram Z, Villano JL.

Cancer Med. 2014 Jun;3(3):592-602. doi: 10.1002/cam4.210. Epub 2014 Feb 14.

19.

Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid.

Lok E, Chung AS, Swanson KD, Wong ET.

Melanoma Res. 2014 Apr;24(2):120-30. doi: 10.1097/CMR.0000000000000045.

20.

A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields.

Butowski N, Wong ET, Mehta MP, Wilson LK.

Semin Oncol. 2013 Dec;40(6):S2-4. doi: 10.1053/j.seminoncol.2013.10.002. Epub 2013 Oct 10.

PMID:
24331200
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk